Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04736056 · ClinicalTrials.gov registry record · NA

Mindfulness and CBT for Sleep

A NA study of Hematologic Malignancy, sponsored by Duke University.

Completed
Registry status
NA
Development phase
57
Enrollment target
1
Study location

NCT04736056: Completed NA study of Hematologic Malignancy, sponsored by Duke University.

NCT04736056 is a NA study of Hematologic Malignancy that has completed, run by Duke University. The registered enrollment target is 57 participants, below the 227-participant average among 48 other Hematologic Malignancy trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04736056, a NA study of Hematologic Malignancy, has completed, sponsored by Duke University.

COMPLETED
Registry status
NA
Development phase
57 participants
Enrollment target
1
Study location

Study Summary

Patients with hematologic cancer frequently report significant difficulties with sleep in the months after discharge from inpatient chemotherapy. Poor sleep quality can contribute to and perpetuate problems with daytime fatigue, pain, and distress that are common among patients with hematologic cancer. There is a need for behavioral interventions that address insomnia and daytime fatigue, pain, and distress once hematologic cancer patients have returned home after inpatient chemotherapy. Mindfulness-Based Therapy for Insomnia (MBTI) is a new approach to treating insomnia. This group-based intervention combines sleep restriction and stimulus control with mindfulness principles and exercises to reduce worry and promote positive responses to insomnia. To date, MBTI has not been applied to patients with hematologic cancer. If MBTI is to meet the needs of hematologic cancer patients, it must be adapted in several ways. First, because hematologic cancer patients are immunosuppressed, MBTI needs to be adapted for one-to-one delivery. Second, because hematologic cancer patients experience significant daytime fatigue, pain, and distress, MBTI needs to be adapted to include systematic training in coping skills for these symptoms. The investigators propose to develop and pilot test an adapted MBTI (MBTI+) protocol for hematologic cancer patients reporting insomnia, fatigue, pain, and/or distress after inpatient chemotherapy. The study will be conducted in two phases. In Phase I, the study team will use focus groups with hematologic cancer patients and hematology-oncology providers to guide development along with user testing with hematologic cancer patients reporting insomnia and daytime symptoms of fatigue, pain, and/or distress. Phase II will involve a small single-arm pilot to examine the feasibility, acceptability, and examine pre- to post-intervention primary (insomnia) and secondary (fatigue, pain, distress, mindfulness, self-efficacy) outcomes of the MBTI+ protocol. MBT

Primary Outcome

Treatment feasibility will be indicated by meeting target study accrual (i.e., 30 participants consented and enrolled for single-arm pilot).

Conditions Studied

Interventions

  • BEHAVIORAL Mindfulness-Based Therapy for Insomnia with Cognitive-Behavioral Symptom Coping Skills

Study Locations (1)

North Carolina

  • Duke Cancer Institute - Durham

Trial Details

FieldValue
Enrollment Target 57 participants
Start Date 2021-04-01
Est. Completion 2023-05-19
Phase NA
Duke University

1,725 total trials

What the finished NCT04736056 record still lists

NCT04736056 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 57 participants, a relatively small participant target, below the 227-participant average among 48 other Hematologic Malignancy trials with a reported enrollment target (75% lower).

The record links to 1 condition, with Hematologic Malignancy appearing as the primary indexed condition, and to 1 intervention - of which Mindfulness-Based Therapy for Insomnia with Cognitive-Behavioral Symptom Coping Skills is the first listed.

NCT04736056 reports a single indexed study location in North Carolina.

Frequently Asked Questions

What is clinical trial NCT04736056 about?

NCT04736056 is a clinical study titled "Mindfulness and CBT for Sleep". Patients with hematologic cancer frequently report significant difficulties with sleep in the months after discharge from inpatient chemotherapy. Poor sleep quality can contribute to and perpetuate problems with daytime fatigue, pain, and distress that are common among patients with hematologic canc...

What is the current status of trial NCT04736056?

This trial is currently completed. It is a NA study. The enrollment target is 57 participants. The study started on 2021-04-01. Estimated completion is 2023-05-19.

What conditions does trial NCT04736056 study?

This clinical trial studies the following conditions: Hematologic Malignancy.

What interventions are being tested in trial NCT04736056?

The interventions under investigation include: Mindfulness-Based Therapy for Insomnia with Cognitive-Behavioral Symptom Coping Skills (BEHAVIORAL).

Who is sponsoring clinical trial NCT04736056?

This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04736056 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hematologic Malignancy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04736056's enrollment target sits among peer trials

57 25th of 48 higher than 24 of 48 other Hematologic Malignancy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Hematologic Malignancy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03521830 · 57 participants · Phase 2

    Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma

  • NCT03587701 · 57 participants · Phase 2

    Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear Disease

  • NCT04104126 · 57 participants · NA

    Blood Flow Restriction Therapy in Achilles Injury

  • NCT04703842 · 57 participants · Phase 1

    Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04736056, the US trial registry maintained by the National Library of Medicine. NCT04736056 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.